Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …

The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …

Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Background Bevacizumab and erlotinib have been demonstrated to prolong overall survival
in patients with non-squamous non-small cell lung cancer (NSCLC). We designed a four …